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Abstract 
A functional cDNA for the human prostacyclin receptor was isolated from a cDNA library of CMK cells, a human megakaryocytic leukaemia 
cell line. The cDNA encodes a protein consisting of 386 amino acid residues with seven putative transmembrane domains and a deduced molecular 
weight of 40,956. [3H]Iloprost specifically bound to the membrane of CHO cells stably expressing the cDNA with a & of 3.3 nM. This binding was 
displaced by unlabelled prostanoids in the order of iloprost = cicaprost >> carbacyclin > prostaglandin El (PGE,) > STA,. PGE2, PGD, and PGF, 
did not inhibit it. Iloprost in a concentration-dependent manner increased the CAMP level and generated inositol trisphosphate in these cells, indicating 
that this human receptor can couple to multiple signal transduction pathways. 
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1. Introduction 
Prostacyclin (PGI,) is an unstable metabolite of ara- 
chidonic acid produced by endothelial cells [l]. It is a 
potent inhibitor of platelet aggregation, and bronchial 
and vascular smooth muscle contraction. These actions 
can counteract the proaggregatory and vasoconstrictor 
activities of another prostanoid, thomboxane (TX) A,, 
and contribute to the maintenance of homeostasis in 
circulation [2]. These activities of PGIz have been 
regarded as being useful for preventing and managing 
diseases uch as cerebral thrombosis and myocardial in- 
farction. For the development of PGI, analogues as ther- 
apeutic agents for cardiovascular and circulatory dis- 
ease, it is necessary to elucidate the precise mechanism 
of PGI, actions in these tissues. The actions of PGI, were 
presumed to be mediated by a cell surface receptor [3,4]. 
The PGI, receptor has been detected on human platelets 
through radioligand binding assays involving 
[3H]iloprost, a stable analogue of PGI, [5-71, and on 
MEG-01 cells, a human megakaryocytic leukaemia cell 
line [8]. Furthermore, several PGI, analogues have been 
reported to have PGI,-like actions on platelets from 
human but not from rat or rabbit, suggesting the exis- 
tence of species difference in PGI, receptor [4,9,10]. 
However, the PGI, receptor has not been isolated, and 
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its molecular characterization has been carried out only 
poorly. Recently, we cloned and characterized the mouse 
PGI, receptor [l 11. In order to elucidate the structural 
and functional characteristics of human receptor, we per- 
formed cDNA cloning and expression analysis of the 
human PGIz receptor. 
2. Materials and methods 
2.1. Molecular cloning of a cDNA for the human PGI, receptor 
A human cDNA library of CMK cells, a human megakaryocytic 
leukaemia cell line [12], was constructed by means of an oligo(dT) 
priming method, and screened by hybridization with a partial fragment 
of the mouse PGI, receptor cDNA [l 11. Hybridization was carried out 
at 56°C for 15 h in 6 x SSC (900 mM NaCl and 90 mM sodium citrate) 
containing 5 x Denhardt’s solution (0.1% Ficoll, 0.1% polyvinyl- 
pyrrolidone, and 0.1% bovine serum albumin) and 0.5% sodium do- 
decyl sulfate, and filters were washed twice at 56°C for 30 min in 
2 x SSC containing 1% sodium dodecyl sulfate. One positive clone, 
MK71, was isolated, and subjected to sequence and expression analysis. 
Nucleotide sequencing was carried out on both strands by the dideoxy 
chain termination method. 
2.2. Expression in CHO cells and ligand binding assay . 
Establishment of Chinese hamster ovary (CHO) cells stably express- 
ing the receptor was performed essentially as described previously [13]. 
the EcoRI insert of MK71 was subcloned into pdKCRdhfr [14], and 
the resultant plasmid DNA was transfected to CHO cells deficient in 
dihydrofolate reductase activity (CHO-dhfr-) by the lipofection method 
[15]. Cell populations expressing the cDNA together with dihydrofolate 
reductase were selected in the a-modification of Eagle’s medium lacking 
ribonucleosides and deoxyribonucleosides and containing penicillin 
(100 units/ml), streptomycin (lOO@ml), and 10% dialyzed fetal bovine 
serum (Cell Culture Laboratories). From these cell populations, clonal 
cell lines were isolated by single-cell cloning. Expression of the human 
cDNA was assessed by Northern blot analysis. The crude membrane 
fraction (100,000 x g pellet fraction) of the clonal cells was used for the 
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[‘Hliloprost (Amersham) binding assay. [3H]Iloprost binding was exam- 
ined by incubating 5Opg protein of the crude membrane in the suspen- 
sion buffer (100 ,~l) with 20 nM (in displacement experiments) or vari- 
ous concentrations (in Scatchard analysis) of [3H]iloprost at 3O’C for 
1 h as described previously [l 11. 
2.3. CAMP assay and measurement of [jH]IP, formation 
A CHO cell clone showing both mRNA expression and [‘Hliloprost 
binding was seeded at 5 x 104/well in a 24-well plate and cultured for 
72 h. Cells (5 x 10’ cells/well) were washed with 0.5 ml of Hepes- 
buffered saline (HBS; 140 mM NaCl, 4.7 mM KCl, 2.2 mM CaCl,, 1.2 
mM KH,PO,, 11 mM glucose, and 15 mM HEPES-NaOH, pH 7.4) and 
preincubated for 10 min in 450 ~1 of the solution containing 1 mM 
3-isobutyl-1-methylxanthine at 37°C. Iloprost in 50 ,~l of the same 
solution was then added and incubated for 10 min at 37°C. The reaction 
was terminated by addition of 500 ~1 of 10% trichloroacetic acid and 
the CAMP level was determined by radioimmunoassay using a 
cAMP[‘~~I] assay system (Amersham). 
For measurement of [3H]inositol trisphosphate (IP,) formation, the 
CHO cell clone was seeded at 3.0 x lO’/well in 6-well plates, cultured 
for 48 h, and then labelled with 1 pCi/ml myo-[2-‘Hlinositol for 12 h 
[16]. Cells were washed twice with HBS and preincubated in 2 ml of 
HBS containing 10 mM LiCl for 5 min at 37°C. The solution was 
aspirated and the reaction was started by adding 1 ml of HBS contain- 
ing 10 mM LiCl and various concentrations of iloprost. After incuba- 
tion at 37’C for 2 min, the medium was quickly aspirated and 1 ml of 
5% trichloroacetic acid was added. Measurement of [‘H]IP, formed was 
performed as described previously [l 11. 
3. Results and discussion 
Fig. 1 shows the nucleotide and deduced amino acid 
sequences of MK71. MK71 contains a 2.0 kb insert 
which has an open reading frame of 1,158 base pairs. The 
deduced amino acid sequence shows that it encodes a 
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protein of 386 amino acids with an estimated molecular 
weight of 40,956. The hydrophobicity profile obtained 
by Kyte and Doolittle’s method [17] indicated that it 
possesses even hydrophobic segments, suggesting that 
it is a guanine nucleotide-binding protein-coupled rho- 
dopsin-type receptor. Two potential N-glycosylation 
sites [18] were found in the N-terminal and the lirst ex- 
tracellular loop regions. 
Membranes of CHO cells expressing the receptor 
showed specific binding of [3H]iloprost, a specific radioli- 
gand for the PGI, receptor. Scatchard analysis of this 
binding yielded a dissociation constant of 3.3 nM and 
maximal binding of 3.2 pmol/mg protein. Fig. 2 shows 
the specificity of this binding. Specific [3H]iloprost bind- 
ing was displaced by unlabelled prostanoids in the order 
of iloprost = cicaprost >> carbacyclin, all of which are 
PGIz agonists, > prostaglandin E, (PGE,) > STA2, a 
TXA, agonist. PGE2, PGDz and PGF,, did not inhibit 
it. This order agrees well with that observed in a displace- 
ment study on human platelets [7,9]. These results dem- 
onstrate that MK71 encodes the human PGIz receptor. 
On signal transduction analysis of the mouse PGI, 
receptor, we found that the receptor can couple to multi- 
ple signalling pathways, adenylate cyclase and phospho- 
lipase C. We next examined the existence of this multiple 
signalling in the case of the human receptor. As shown 
in Fig. 3a, iloprost generated CAMP in a concentration- 
dependent manner in CHO cells stably expressing the 
receptor. Furthermore, as shown in Fig. 3b, iloprost gen- 
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Fig. 1. Nucleotide and deduced amino acid sequences of MK71. The deduced amino acid sequence is shown beneath the nucleotide sequence using 
a single-letter code. The positions of the putative transmembrane segments, I-VII, are underlined. Triangles, potential N-glycosylation sites; parallel 
crosses, potential sites of phosphorylation by protein kinase C. 
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Fig. 2. Displacement of the specific binding of [-‘H]iloprost in mem- 
branes of CHO cells expressing MK71. Membranes of CHO cells ex- 
pressing MK71 were incubated with 20 nM [-‘H]iloprost and various 
unlabelled prostanoids at the indicated concentrations. Unlabelled pro- 
stanoids are indicated as follows. o, iloprost; l , cicaprost; A, carbacy- 
clin; A, PGE,; q , PGE,; n , PGD,; o, STA,; +, PGF,,. 
erated [3H]IP3 in a concentration-dependent manner in 
CHO cells expressing the receptor, suggesting that it 
evoked phosphatidylinositol hydrolysis. In previous 
studies, PGI, or its analogues evoked an increase in the 
cytosolic Ca2+ concentration in human cell lines, MEG- 
01 cells [8], and HEL cells, a pluripotent human 
erythroleukaemia cell line [19]. The present study re- 
vealed that the human PGI, receptor as well as the mouse 
receptor can couple to multiple signalling pathways, 
adenylate cyclase and phospholipase C. 
Fig. 4 shows a comparison of the amino acid se- 
quences of the human and mouse PG12 receptors. The 
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Fig. 3. Effect of iloprost on the CAMP level (a) and IP, formation (b) 
in MK71-expressing CHO cells. CHO cells were incubated with the 
indicated concentrations of iloprost, and then the CAMP level and 
[3H]IP3 formation were determined as described in section 2. The results 
shown are the means of triplicate determinations. 
sequence of the human PGI, receptor is 73% identical to 
that of the mouse receptor. This sequence identity be- 
tween the spieces is relatively lower than that observed 
in other G protein-coupled receptors. Furthermore, one 
of the structural features of the human PGI, receptor is 
deletion of the N-terminal first 30 amino acids observed 
in the mouse receptor. Although we could not detect the 
difference in binding characters of the human and mouse 
receptors in this study, it is likely that two PGIz receptors 
may show different specificities of binding in the case of 
using other kinds of PGI, analogues. In fact, several 
PGI, analogues have been reported to have PGI,-like 
actions on platelets from human but not from rat or 
rabbit, suggesting the existence of species difference in 
PG12 receptor [4,9, lo]. Further investigations hould be 
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Fig. 4. Comparison of the amino acid sequences of the human (upper) and mouse (lower) PG12 receptors. Identical amino acid residues are indicated 
by asterisks and non-identical residues are shown in the mouse sequence. The seven transmembrane domains are indicated above the amino acid 
sequences. 
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Fig.S.Comparisonoftheaminoacidsequencesamonghumanprostanoidreceptors.ThededucedaminoacidsequencesofthehumanPGI,receptor 
(hIP), human EP, (hEP,), human EPg (hEP,), human EP, (hEP,), human PGF receptor (hFP), and human TXA2 receptor (hTP) are shown aligned 
to optimize homology. Identical amino acid residues in four or more sequences are indicated by bold characters. The seven transmembrane domains 
are indicated above the amino acid sequences. 
made to conclude whether the spieces difference exists or 
not in the PGI, receptor. 
Fig. 5 shows a comparison of the amino acid se- 
quences among the cloned human prostanoid receptors. 
The human IP receptor shares 37% overall amino acid 
identity with human EP, [20] receptor and 34,3 1,29, and 
28% identity with human TP [21], EP, [22], EP, [23], and 
FP [24] receptors, respectively. The amino acid identity 
is mainly restricted to the transmembrane domains, espe- 
cially the VII, which is the most conserved, with the V 
being the least conserved. The conserved residues are 
presumed to be important in the recognition of the com- 
mon sturctures in prostanoid ligands or in the formation 
of the receptor structure. For instance, Arg-279, con- 
served among all eicosanoid receptors, has been pro- 
posed to be the counter-ligand for the prostanoid car- 
boxy1 moiety [13,21]. Among these prostanoid receptors, 
the human IP receptor has the common sequences espe- 
cially with EP2 receptor; GVVGN in the I, VLFCALP 
in the IV, and YAG in the V. Furthermore, within the 
most highly conserved region in the VII, proline 285 is 
conserved only in the IP and EP, receptors, while the 
other prostanoid receptors have glutamine residue for 
proline. Therefore, the human IP receptor is most highly 
related to the EP, receptor, and it is interesting that these 
two receptors can couple to the stimulation of adenylate 
cyclase [20,25]. The human IP receptor also shares sev- 
eral of the features common to all other G protein-cou- 
pled receptors which are thought to be important in 
defining the topography and functions of this family [26]. 
For instance, there is one potential N-glycosylation site 
(Asn-7) in the putative extracellular amino terminus 
(Fig. l), and aspartic acid (Asp-60) in the domain II. 
Conserved cysteine residues are found in the extracellu- 
lar loops 1 and 2 (Cys-92 and Cys-170). The intracellular 
loops and the carboxyl terminal tail contain a number of 
serine and threonine residues (Fig. l), potential phospho- 
rylation sites, which may be involved in receptor desensi- 
tization [27]. 
In summary, we presented here the structure and func- 
tion of the human PGI, receptor. The results of this 
study will be very useful for designing specific PGI, ag- 
onists or antagonists for therapeutic purposes in hu- 
mans. 
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